MIDODRINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Midodrine Hydrochloride, and what generic alternatives are available?
Midodrine Hydrochloride is a drug marketed by Alembic, Apotex, Aurobindo Pharma Ltd, Chartwell Rx, Impax Pharms, Mankind Pharma, Mylan Pharms Inc, Novugen, Par Pharm Inc, Rubicon, Thinq Pharm-cro Pvt, Xiromed, and Zydus. and is included in thirteen NDAs.
The generic ingredient in MIDODRINE HYDROCHLORIDE is midodrine hydrochloride. There are thirteen drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the midodrine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Midodrine Hydrochloride
A generic version of MIDODRINE HYDROCHLORIDE was approved as midodrine hydrochloride by MYLAN PHARMS INC on September 10th, 2003.
Summary for MIDODRINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 13 |
NDAs: | 13 |
Finished Product Suppliers / Packagers: | 26 |
Raw Ingredient (Bulk) Api Vendors: | 87 |
Clinical Trials: | 99 |
Patent Applications: | 285 |
Formulation / Manufacturing: | see details |
DailyMed Link: | MIDODRINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for MIDODRINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Noha Mansour | Phase 4 |
Ningbo No. 1 Hospital | N/A |
First Affiliated Hospital, Sun Yat-Sen University | N/A |
Pharmacology for MIDODRINE HYDROCHLORIDE
Drug Class | alpha-Adrenergic Agonist |
Mechanism of Action | Adrenergic alpha-Agonists |